Clinical trial
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult…
NCT00111436 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111436 |
|---|---|
| Title | Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects |
| Official title | An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 912 |
| Start date | Apr 1, 2003 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | May 23, 2005 |
| Last update posted | Apr 26, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: